Amphastar Pharmaceuticals Statistics
Share Statistics
Amphastar Pharmaceuticals has 47.14M
shares outstanding. The number of shares has increased by -2.56%
in one year.
| Shares Outstanding | 47.14M |
| Shares Change (YoY) | -2.56% |
| Shares Change (QoQ) | -0.9% |
| Owned by Institutions (%) | 72.87% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 1,323 |
| FTD / Avg. Volume | 0.22% |
Short Selling Information
The latest short interest is 4.01M, so 8.5% of the outstanding
shares have been sold short.
| Short Interest | 4.01M |
| Short % of Shares Out | 8.5% |
| Short % of Float | 16.84% |
| Short Ratio (days to cover) | 6.13 |
Valuation Ratios
The PE ratio is 11.27 and the forward
PE ratio is 7.29.
Amphastar Pharmaceuticals's PEG ratio is
0.73.
| PE Ratio | 11.27 |
| Forward PE | 7.29 |
| PS Ratio | 2.52 |
| Forward PS | 1.3 |
| PB Ratio | 2.46 |
| P/FCF Ratio | 10.43 |
| PEG Ratio | 0.73 |
Financial Ratio HistoryEnterprise Valuation
Amphastar Pharmaceuticals has an Enterprise Value (EV) of 2.3B.
| EV / Sales | 3.22 |
| EV / EBITDA | 8.28 |
| EV / EBIT | 10.77 |
| EV / FCF | 13.33 |
Financial Position
The company has a current ratio of 3.07,
with a Debt / Equity ratio of 0.89.
| Current Ratio | 3.07 |
| Quick Ratio | 2.19 |
| Debt / Equity | 0.89 |
| Debt / EBITDA | 2.35 |
| Debt / FCF | 3.77 |
| Interest Coverage | 6.77 |
Financial Efficiency
Return on Equity is 21.78% and Return on Invested Capital is 12.28%.
| Return on Equity | 21.78% |
| Return on Assets | 10.11% |
| Return on Invested Capital | 12.28% |
| Revenue Per Employee | $351,486.19 |
| Profits Per Employee | $78,658.28 |
| Employee Count | 2,028 |
| Asset Turnover | 0.45 |
| Inventory Turnover | 2.2 |
Taxes
| Income Tax | 29.67M |
| Effective Tax Rate | 15.64% |
Stock Price Statistics
The stock price has increased by -39.26% in the
last 52 weeks. The beta is 0.78, so Amphastar Pharmaceuticals's
price volatility has been higher than the market average.
| Beta | 0.78 |
| 52-Week Price Change | -39.26% |
| 50-Day Moving Average | 25.24 |
| 200-Day Moving Average | 37.39 |
| Relative Strength Index (RSI) | 56.96 |
| Average Volume (20 Days) | 612,040 |
Income Statement
In the last 12 months, Amphastar Pharmaceuticals had revenue of 712.81M
and earned 159.52M
in profits. Earnings per share was 3.29.
| Revenue | 712.81M |
| Gross Profit | 373.86M |
| Operating Income | 205.42M |
| Net Income | 159.52M |
| EBITDA | 277.31M |
| EBIT | 220.11M |
| Earnings Per Share (EPS) | 3.29 |
Full Income StatementBalance Sheet
The company has 151.61M in cash and 650.55M in
debt, giving a net cash position of -498.94M.
| Cash & Cash Equivalents | 151.61M |
| Total Debt | 650.55M |
| Net Cash | -498.94M |
| Retained Earnings | 568.79M |
| Total Assets | 1.63B |
| Working Capital | 388.91M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was 213.39M
and capital expenditures -41.04M, giving a free cash flow of 172.34M.
| Operating Cash Flow | 213.39M |
| Capital Expenditures | -41.04M |
| Free Cash Flow | 172.34M |
| FCF Per Share | 3.56 |
Full Cash Flow StatementMargins
Gross margin is 52.45%, with operating and profit margins of 28.82% and 22.38%.
| Gross Margin | 52.45% |
| Operating Margin | 28.82% |
| Pretax Margin | 26.62% |
| Profit Margin | 22.38% |
| EBITDA Margin | 38.9% |
| EBIT Margin | 28.82% |
| FCF Margin | 24.18% |
